TNDM Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
254.6M
+3.0%
247.2M
-14.9%
290.4M
+16.5%
249.3M
+3.6%
240.7M
Cost of Revenue
109.8M
-0.6%
110.4M
-10.2%
122.9M
+6.9%
115.0M
+0.1%
114.8M
Gross Profit
144.8M
+5.8%
136.8M
-18.3%
167.5M
+24.7%
134.3M
+6.7%
125.9M
Operating Expenses
158.6M
+2.8%
154.2M
-3.1%
159.2M
+1.3%
157.2M
-11.5%
177.7M
R&D
46.9M
+1.9%
46.0M
-0.1%
46.1M
-5.4%
48.7M
+1.2%
48.1M
SG&A
111.6M
+3.2%
108.2M
-4.3%
113.1M
+4.3%
108.4M
-1.1%
109.6M
Operating Income
-13792000
+20.9%
-17434000
-310.2%
8.3M
+136.3%
-22863000
+55.9%
-51810000
EBITDA
-9322000
+27.9%
-12930000
-201.1%
12.8M
+169.6%
-18370000
+33.2%
-27492000
Net Income
-21168000
-3.8%
-20393000
-3362.3%
-589000
+97.2%
-21165000
+59.6%
-52400000
EPS (Basic)
$-0.31
-3.3%
$-0.30
-2900.0%
$-0.01
+96.8%
$-0.31
+60.3%
$-0.78
EPS (Diluted)
$-0.31
-3.3%
$-0.30
-2900.0%
$-0.01
+96.8%
$-0.31
+60.3%
$-0.78
Shares (Diluted)
69.0M
+0.9%
68.4M
+0.5%
68.0M
+0.6%
67.7M
+0.9%
67.0M
Tandem Diabetes Care (TNDM) โ€” Financials